Literature DB >> 28096154

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Zackery P Bulman1,2, Neang S Ly1,2, Justin R Lenhard3, Patricia N Holden1,2, Jürgen B Bulitta4, Brian T Tsuji5,2.   

Abstract

The impact of quorum sensing on polymyxin and azithromycin pharmacodynamics was assessed in Pseudomonas aeruginosa PAO1 and an isogenic rhlR/lasR double knockout. For polymyxin B, greater killing against the rhlR/lasR knockout than against PAO1 was observed at 108 CFU/ml (polymyxin B half-maximal effective concentration [EC50], 5.61 versus 12.5 mg/liter, respectively; P < 0.005). Polymyxin B combined with azithromycin (256 mg/liter) was synergistic against each strain, significantly reducing the respective polymyxin B EC50 compared to those with monotherapy (P < 0.005), and is a promising strategy by which to combat P. aeruginosa.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  P. aeruginosa; Pseudomonas aeruginosa; azithromycin; colistin; mechanism-based modeling; pharmacodynamics; polymyxin B; polymyxins; quorum sensing

Mesh：

Substances：

Year:  2017        PMID： 28096154      PMCID： PMC5365695          DOI： 10.1128/AAC.00096-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

1.  Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.

Authors:  K Tateda; R Comte; J C Pechere; T Köhler; K Yamaguchi; C Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Cloning and functional characterization of the Pseudomonas aeruginosa rhlC gene that encodes rhamnosyltransferase 2, an enzyme responsible for di-rhamnolipid biosynthesis.

Authors:  R Rahim; U A Ochsner; C Olvera; M Graninger; P Messner; J S Lam; G Soberón-Chávez
Journal:  Mol Microbiol       Date:  2001-05       Impact factor: 3.501

3.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

5.  Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.

Authors:  S Bratu; J Quale; S Cebular; R Heddurshetti; D Landman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

6.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

7.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.

Authors:  Joseph B McPhee; Shawn Lewenza; Robert E W Hancock
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

9.  Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Authors:  C H Ballow; G W Amsden; V S Highet; A Forrest
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079
View more
  4 in total

1.  Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib.

Authors:  David A Butler; Amisha P Rana; Fiorella Krapp; Shitalben R Patel; Yanqin Huang; Egon A Ozer; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

2.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

Review 3.  Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective.

Authors:  Benjamin Rémy; Sonia Mion; Laure Plener; Mikael Elias; Eric Chabrière; David Daudé
Journal:  Front Pharmacol       Date:  2018-03-07       Impact factor: 5.810

4.  Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae.

Authors:  Yanqin Huang; Karol Sokolowski; Amisha Rana; Nidhi Singh; Jiping Wang; Ke Chen; Yinzhi Lang; Jieqiang Zhou; Neera Kadiyala; Fiorella Krapp; Egon A Ozer; Alan R Hauser; Jian Li; Jürgen B Bulitta; Zackery P Bulman
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.